Background Bioresorbable vascular scaffolds (BVS) offer the potential to improve long-term
outcomes of percutaneous coronary intervention after their complete bioresorption …

State-of-the-art drug-eluting metal stents are the gold standard for interventional treatment of
coronary artery disease. Although they overcome some disadvantages and limitations of …

In the present study, pure zinc stents were implanted into the abdominal aorta of rabbits for
12 months. Multiscale analysis including micro-CT, scanning electron microscopy (SEM) …

Background Despite rapid dissemination of an everolimus-eluting bioresorbable scaffold for
treatment for coronary artery disease, no data from comparisons with its metallic stent …

Gruntzig in 1977 was a huge leap forward in cardiovascular medicine and undoubtedly will
always be remembered as a revolution in the field of revascularization. However, this …

Background: The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3
years after coronary artery implantation. The safety and effectiveness of BVS through this …

Objectives: The aim of this study was to demonstrate that the prevention of early scaffold
area shrinkage of the ABSORB BVS (Rev. 1.1, Abbott Vascular, Santa Clara, California) was …

In published post-mortem pathological studies, more than two-thirds of acute coronary
events are associated with the rupture of lipid-rich, voluminous, and outwardly remodelled …

Drug-eluting bioresorbable scaffolds (BRSs) may in the near future change drastically the
landscape of percutaneous coronary revascularization. 1 In 1977, when Andreas Gruentzig …

Current generation of drug-eluting stents has significantly improved the outcomes of
percutaneous coronary intervention by substantially reducing in-stent restenosis and stent …